Repare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunresertib and camonsertib that disappointed investors.
The lunresertib and camonsertib combination achieved a 25.9% objective response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer in the trial. The study included heavily pretreated patients.
Shares slumped 57% following a surge in intraday trading volume to over 3.6 million from a daily average of about 165,000.
Inovio Pharmaceuticals (INO) said Friday it priced an offering of 10 million shares and accompanying warrants to purchase the same number of shares at $3 per share and accompanying warrant.
Shares slumped 39%, with intraday trading volume at over 7.8 million versus the stock's daily average of about 387,000.
Candel Therapeutics (CADL) sank past 30% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.
More than 15.1 million shares traded intraday compared with a daily average of about 2.4 million.
Price: 1.71, Change: -2.26, Percent Change: -56.95
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。